NCT04391829

Brief Summary

The objectives of the study, are to describe detection of SARS-CoV-2 in the semen of COVID-19 positive patients, the duration of positive semen and to investigate the impact on semen quality, thereby providing insights into the early impact on male reproductive function.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for not_applicable covid19

Timeline
Completed

Started Aug 2020

Typical duration for not_applicable covid19

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 13, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 18, 2020

Completed
4 months until next milestone

Study Start

First participant enrolled

August 31, 2020

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2021

Completed
Last Updated

October 28, 2020

Status Verified

May 1, 2020

Enrollment Period

1 year

First QC Date

May 13, 2020

Last Update Submit

October 26, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • detection of SARS-CoV-2 in the semen

    detection of SARS-CoV-2 in the semen of men positive for SARS-CoV-2 on nasopharyngeal swab

    within 7 days after positive testing for SARS-CoV-2

Secondary Outcomes (7)

  • duration of SARS-CoV-2 presence in semen

    from first positive semen testing until first negative semen testing, upto 15 weeks

  • semen viscosity

    from first until last semen analysis, upto 15 weeks

  • semen volume

    from first until last semen analysis, upto 15 weeks

  • semen pH

    from first until last semen analysis, upto 15 weeks

  • Sperm motility

    from first until last semen analysis, upto 15 weeks

  • +2 more secondary outcomes

Study Arms (1)

SARS-CoV-2 positive men

EXPERIMENTAL

Men who are tested positive for SARS-CoV-2 by PCR testing on nasopharyngeal swab.

Diagnostic Test: Ejaculated semen sample

Interventions

SARS-CoV-2 positive men will be asked to give an ejaculated semen sample, within the seven days after positive testing. Semen samples will be performed every 7 days, until 2 semen PCR tests are negative and will be retested after 3 months.

SARS-CoV-2 positive men

Eligibility Criteria

Age18 Years - 50 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Male
  • PCR on nasopharyngeal swab positive for SARS-CoV-2
  • Age: ≥ 18y - ≤ 50y
  • Signed informed consent
  • When undergoing ART treatment: ICSI treatment

You may not qualify if:

  • Negative test of SARS-CoV-2 on nasopharyngeal swab sample
  • History of immunosuppression
  • Impossibility to deliver a semen sample at UZ Brussel on a weekly base
  • When undergoing ART treatment: IVF treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UZ Brussel

Brussels, 1090, Belgium

RECRUITING

Related Publications (1)

  • Li D, Jin M, Bao P, Zhao W, Zhang S. Clinical Characteristics and Results of Semen Tests Among Men With Coronavirus Disease 2019. JAMA Netw Open. 2020 May 1;3(5):e208292. doi: 10.1001/jamanetworkopen.2020.8292.

MeSH Terms

Conditions

COVID-19Coronavirus Infections

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Michael De Brucker, MD PHD

    UZ Brussels

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Michael De Brucker, MD PHD

CONTACT

Valerie Uvin, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 13, 2020

First Posted

May 18, 2020

Study Start

August 31, 2020

Primary Completion

August 31, 2021

Study Completion

August 31, 2021

Last Updated

October 28, 2020

Record last verified: 2020-05

Data Sharing

IPD Sharing
Will not share

Locations